Europe PMC
Nothing Special   »   [go: up one dir, main page]

Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Psoriasis assessment tools in clinical trials.

Author information

Affiliations

  • 1. Wake Forest University School of Medicine, Department of Dermatology, Winston-Salem, NC 27157-1071, USA.
      Authors
    • Feldman SR 1
    (1 author)

ORCIDs linked to this article

Annals of the Rheumatic Diseases, 01 Mar 2005, 64 Suppl 2:ii65-8; discussion ii69-73
https://doi.org/10.1136/ard.2004.031237 PMID: 15708941 PMCID: PMC1766877

ReviewFree full text in Europe PMC

Abstract 

In clinical practice, broad global assessments of psoriasis disease activity and its effect on patients' quality of life are used to assess the severity of patients' disease and their response to treatment. In clinical trials, more objective, validated instruments are required. Several such instruments have been developed and continue to be developed to provide an assessment of the severity of the skin lesions. Because a lesion's impact on patients' lives varies widely among patients, there has been growing recognition of the need to measure the quality of life impact of the disease along with the severity of the lesions.

Free full text 

Logo of annrheumdLink to Publisher's site
Ann Rheum Dis. 2005 Mar; 64(Suppl 2): ii65–ii68.
PMCID: PMC1766877
PMID: 15708941

Psoriasis assessment tools in clinical trials

S Feldman and G Krueger
Copyright and License information Disclaimer

Abstract

In clinical practice, broad global assessments of psoriasis disease activity and its effect on patients' quality of life are used to assess the severity of patients' disease and their response to treatment. In clinical trials, more objective, validated instruments are required. Several such instruments have been developed and continue to be developed to provide an assessment of the severity of the skin lesions. Because a lesion's impact on patients' lives varies widely among patients, there has been growing recognition of the need to measure the quality of life impact of the disease along with the severity of the lesions.

Full Text

The Full Text of this article is available as a PDF (62K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Fredriksson T, Pettersson U. Severe psoriasis--oral therapy with a new retinoid. Dermatologica. 1978;157(4):238–244. [Abstract] [Google Scholar]
  • Ashcroft DM, Wan Po AL, Williams HC, Griffiths CE. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol. 1999 Aug;141(2):185–191. [Abstract] [Google Scholar]
  • Feldman Steven R. The design of clinical trials in psoriasis: lessons for clinical practice. J Am Acad Dermatol. 2003 Aug;49(2 Suppl):S62–S65. [Abstract] [Google Scholar]
  • Carlin Christopher S, Feldman Steven R, Krueger James G, Menter Alan, Krueger Gerald G. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol. 2004 Jun;50(6):859–866. [Abstract] [Google Scholar]
  • Langley Richard G, Ellis Charles N. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol. 2004 Oct;51(4):563–569. [Abstract] [Google Scholar]
  • Carlin Christopher S, Callis Kristina P, Krueger Gerald G. Efficacy of acitretin and commercial tanning bed therapy for psoriasis. Arch Dermatol. 2003 Apr;139(4):436–442. [Abstract] [Google Scholar]
  • Gottlieb Alice B, Chaudhari Umesh, Baker Daniel G, Perate Michelle, Dooley Lisa T. The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): a comparison. J Drugs Dermatol. 2003 Jun;2(3):260–266. [Abstract] [Google Scholar]
  • Krueger JG, Wolfe JT, Nabeya RT, Vallat VP, Gilleaudeau P, Heftler NS, Austin LM, Gottlieb AB. Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells. J Exp Med. 1995 Dec 1;182(6):2057–2068. [Europe PMC free article] [Abstract] [Google Scholar]
  • Kirby B, Richards HL, Woo P, Hindle E, Main CJ, Griffiths CE. Physical and psychologic measures are necessary to assess overall psoriasis severity. J Am Acad Dermatol. 2001 Jul;45(1):72–76. [Abstract] [Google Scholar]
  • Anderson RT, Aaronson NK, Wilkin D. Critical review of the international assessments of health-related quality of life. Qual Life Res. 1993 Dec;2(6):369–395. [Abstract] [Google Scholar]
  • Brazier J, Jones N, Kind P. Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire. Qual Life Res. 1993 Jun;2(3):169–180. [Abstract] [Google Scholar]
  • Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994 May;19(3):210–216. [Abstract] [Google Scholar]
  • Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol. 1997 Nov;133(11):1433–1440. [Abstract] [Google Scholar]
  • Rapp SR, Feldman SR, Exum ML, Fleischer AB, Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999 Sep;41(3 Pt 1):401–407. [Abstract] [Google Scholar]
  • Ashcroft DM, Li Wan Po A, Williams HC, Griffiths CE. Quality of life measures in psoriasis: a critical appraisal of their quality. J Clin Pharm Ther. 1998 Oct;23(5):391–398. [Abstract] [Google Scholar]
  • Kirby B, Fortune DG, Bhushan M, Chalmers RJ, Griffiths CE. The Salford Psoriasis Index: an holistic measure of psoriasis severity. Br J Dermatol. 2000 Apr;142(4):728–732. [Abstract] [Google Scholar]
  • Ellis Charles N, Mordin Margaret M, Adler Ellen Y. Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial. Am J Clin Dermatol. 2003;4(2):131–139. [Abstract] [Google Scholar]
  • Gordon Kenneth B, Papp Kim A, Hamilton Tiffani K, Walicke Patricia A, Dummer Wolfgang, Li Nicole, Bresnahan Brian W, Menter Alan. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA. 2003 Dec 17;290(23):3073–3080. [Abstract] [Google Scholar]
  • Leonardi Craig L, Powers Jerold L, Matheson Robert T, Goffe Bernard S, Zitnik Ralph, Wang Andrea, Gottlieb Alice B. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003 Nov 20;349(21):2014–2022. [Abstract] [Google Scholar]
  • Gottlieb Alice B, Matheson Robert T, Lowe Nicholas, Krueger Gerald G, Kang Sewon, Goffe Bernard S, Gaspari Anthony A, Ling Mark, Weinstein Gerald D, Nayak Anjuli, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003 Dec;139(12):1627–1632. [Abstract] [Google Scholar]
  • Gottlieb Alice B. Infliximab for psoriasis. J Am Acad Dermatol. 2003 Aug;49(2 Suppl):S112–S117. [Abstract] [Google Scholar]
  • Gottlieb Alice B, Chaudhari Umesh, Mulcahy Lisa D, Li Shu, Dooley Lisa T, Baker Daniel G. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol. 2003 Jun;48(6):829–835. [Abstract] [Google Scholar]
  • Elder James T. Psoriasis clinical registries, genetics, and genomics. Ann Rheum Dis. 2005 Mar;64 (Suppl 2):ii106–ii107. [Europe PMC free article] [Abstract] [Google Scholar]
Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

Full text links 

Read article at publisher's site: https://doi.org/10.1136/ard.2004.031237

Read article for free, from open access legal sources, via Unpaywall: https://ard.bmj.com/content/annrheumdis/64/suppl_2/ii65.full.pdfUnpaywall

Citations & impact 

Impact metrics

228
Citations
Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/2416715
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/2416715

Article citations

Go to all (228) article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.